Oramed Pharmaceuticals Inc. announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA , on May 31, 2023.
|
NEW YORK, May 18, 2023 /PRNewswire/ --Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA, on May 31, 2023. The presentation will include an overview of Oramed's oral delivery technology as well as insights from the Company's recent Phase 3 oral insulin clinical trials. 
Presentation Details: Novel Therapies for Type 2 Diabetes & Obesity Summit Date: Wednesday, May 31, 2023 Time: 1:30 p.m. E.T. Location: Hyatt Regency Boston, Boston, MA For more information regarding the summit and the presentation, please visit the Summit's website: Home - Novel Therapies for Type 2 Diabetes & Obesity Summit 2023 (t2d-obesity-summit.com) About Oramed Pharmaceuticals Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. The Company's novel Protein Oral Delivery (POD™) technology is designed to protect drug integrity and increase absorption. Oramed has offices in the United States and Israel. For more information, please visit www.oramed.com. Company Contact: Logo - https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
SOURCE Oramed Pharmaceuticals Inc. |
||
Company Codes: NASDAQ-SMALL:ORMP, TelAviv:ORMP |
View original content:
